ACC-9358

In this study we evaluated the clinical pharmacology of intravenous ACC-9358, a new antiarrhythmic drug derived from a Chinese herbal remedy. In a first-study phase, 0.125 to 1.0 mg/kg during 10 minutes was administered to six patients with chronic nonsustained ventricular arrhythmias. These data were then used to design 3-hour infusions to maintain stable plasma concentrations: these infusions suppressed arrhythmias by 90% or greater for 2 1/2 hours or more at plasma concentrations of 114 to 1010 ng/ml (mean, 400 +/- 421 ng/ml [SD]), and with QRS interval increases of 2.5% to 8.8% (5.1% +/- 2.9%). Mean clearance was 478 +/- 151 ml/min, and elimination half-life was 19.1 +/- 6.1 hours. ACC-9358 did not produce adverse effects in this study. ACC-9358 shows antiarrhythmic activity in humans at concentrations that prolong QRS only slightly and do not alter rate-corrected QT; further studies in other patient populations, at dosages and plasma concentrations defined here, are required to establish a clinical role for ACC-9358. The pharmacokinetically based dose-ranging approach allowed the safe initial evaluation of ACC-9358 in patients.

1. Falk RH, Knowlton AA, Bernard SA, Gotlieb NE, Battinelli NJ. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. Ann Inrem Med 1978;106:503-506. 2. Weiner P, Bassan MM, Jarchovsky J, Iusim S, Plavnick L. Clinical course of acute atria1 fibrillation treated with rapid digitalization. Am Hearr J 1983; 105223-227. 3. Mallis GI, Schmidt DH, Lindebaum J. Superior bioavailability of digoxin solution in capsules. Clin Pharmacol Ther 1976;18:761-768. 4. Rosen MR. Wu AL, Hoffman BF. Electrophysiology and pharmacology of cardiac arrhythmias: IV. Cardiac antiarrhythmic and toxic effects of digitalis. Am Heart J 1975;89:391-399. 5. Meijler FL. An “account” of digitalis and atrial fibrillation. JACC 1985; S(suppl A):60A-68A. 6. Allesie M, Lammers W, Smeets J, Bonke F, Hollen J. Total mapping of atrial excitation during acetylcholine-induced atria1 flutter and fibrillation in the iwlated canine heart. In: Kulbertus HE, Olsson SB, Schlepper M, eds. Atrial Fibrillation. Moltl41:981-988.